{ "items": [ "\n\n
Chandna J. et al, (2022), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74, S35 - S43
\n \n \n \n\n \n
\n \n \nGelaye B. et al, (2022), EUROPEAN NEUROPSYCHOPHARMACOLOGY, 63, E24 - E24
\n \n \n \n\n \n
\n \n \nMwangala PN. et al, (2022), Wellcome open research, 7
\n \n \n \n\n \n
\n \n \nKim HA. et al, (2022), EUROPEAN NEUROPSYCHOPHARMACOLOGY, 63, E149 - E149
\n \n \n \n\n \n
\n \n \nWanjala SW. et al, (2021), Global health research and policy, 6
\n \n \n \n\n \n
\n \n \nEgesa IJ. et al, (2021), Epilepsia Open
\n \n \n \n\n \n
\n \n \nNyongesa MK. et al, (2021), Substance abuse treatment, prevention, and policy, 16
\n \n \n \n\n \n
\n \n \nBegley C. et al, (2021), EPILEPSIA, 62, 6 - 6
\n \n \n \n\n \n
\n \n \nSen A. et al, (2021), Lancet (London, England), 398
\n \n \n \n\n \n
\n \n \nTsigebrhan R. et al, (2021), BMC family practice, 22
\n \n \n \n\n \n
\n \n \nKipkemoi P. et al, (2021), EUROPEAN NEUROPSYCHOPHARMACOLOGY, 51, E38 - E39
\n \n \n \n\n \n
\n \n \nAndraus M. et al, (2021), Epilepsy & behavior : E&B, 123
\n \n \n \n\n \n
\n \n \nMwangala PN. et al, (2021), BMJ open, 11
\n \n \n \n\n \n
\n \n \nAbuga JA. et al, (2021), Developmental Medicine & Child Neurology
\n \n \n \n\n \n
\n \n \nNewton CR., (2021), Developmental Medicine & Child Neurology, 63, 1011 - 1011
\n \n \n \n\n \n
\n \n \nLangat NK. et al, (2021), Wellcome Open Research, 6, 200 - 200
\n \n \n \n\n \n
\n \n \nShlobin NA. et al, (2021), Journal of the neurological sciences, 427
\n \n \n \n\n \n
\n \n \nKariuki SM. et al, (2021), Seizure, 89, 51 - 55
\n \n \n \n\n \n
\n \n \nOlusanya BO. et al, (2021), The Lancet. Global health, 9
\n \n \n \n\n \n
\n \n \nTriki CC. et al, (2021), Journal of Neurology
\n \n \n \n\n \n
\n \n \n